Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Huge huge news!! Goes over $10 tomorrow
Loaded the boat, $SGMO is taking off very soon. Quintupled bottom. Any positive news and this breaks out on air!
wow,,,fda gives us approval $$$$$$$$
What happen to this stock? where are everyone?
Will SGMO see $1s soon?
here we go $5.09 pivy boooom myop$$$
Thanks. This one did bounce well. I took profits at 4.55. It could definitely get higher. I just need to let things settle with my account before there's an opportunity on LABD again.
Congrats on the entry here (so far) on SGMO. News suddenly showed up to help give it a boost.
It could be set up for break out higher toward 5+. But if it fails to do so, be vigilant & apply a stop-loss (trailing performance) at a certain point so you can at least lock in some profits above your cost.
I hesitated on sidelines too much in late August while this was one of my top watch list stocks.
My instinct & charts were telling me this was a buy in low 4's last week, but I was floundering in non-activity.
I plan to get back to being more active again soon.
gonna explode thru $8 myop $$$$
I'm still in with 4.23 avg
It looked like an established bottom on the 25th. Back in at 4.26 this morning.
Still holding not gonna miss the train to 7.00
From the action today I think it may have been the bottom
That's awesome. You thinking that's the short-term bottom? I started to get frustrated when I missed my targets. Time for me to take a step back and watch until I get my head right again.
I got some at 4.28
Had to pull out. Lookong for entry if this levels off. After listening to the webcast by the company, I can't wait to see the new direction for the company pay off.
Loving the upside bounce on this one after the sell off. Just hoping it last a couple days to rise above 5.3.
Don't want to get burned by settlement days and PDT rules.
I believe she will rise once again.
Wish me luck see you all when youre buying at 5.00
Im in 4.43 not gonna miss the train this time
Do you think sgmo is smart money right meow?
DUMP YOUR STOCKS! THE HIV VACCINE ISN'T DOING WELL!!!!
Rumor has it, the drug isn't doing well as it first hoped.
Dump while the going is good!
Smart money what you think about sgmo
SGMO 2 days down! Going to run big tomorrow!
* * $SGMO Video Chart 09-11-15 * *
Link to Video - click here to watch the technical chart video
SHORTS CRACKIN THE SGMO SAFE
911 PRINT HOD LOL
SGMO
SGMO...NICE $1 MOVE BETWEEN 11.50AM TO 12.10PM
Current assets over $220M.
Some nice block buys recently, on watch for reversal of longterm trend.
New Vaccine for HIV
http://www.sciencealert.com/potential-new-vaccine-blocks-every-strain-of-hiv
HIV Reservoir reduced and removed ...latest break through news from sangamo http://investor.sangamo.com/releasedetail.cfm?ReleaseID=913218
Holding well. Can't wait to see $15
It will go reach $15 and beyond...wait next 15 days...
Can't wait to see $15+
SGMO
SGMO, will go up more.. GTI
Loving my buy at $12.39. Undervalued here
44% increase in salary
http://www.conferencecalltranscripts.org/proxy/summary2/?id=1642854
Study of potential HIV 'cure' wins FDA nod
http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/03/hiv-aids-cirm-stem-cells-sangamo-sgmo-usc.html?ana=yahoo
cool...
SJO
$SGMO DD Notes ~ http://www.ddnotesmaker.com/SGMO
bullish
falling wedge breakout
$SGMO recent news/filings
## source: finance.yahoo.com
Fri, 12 Dec 2014 12:31:23 GMT ~ Sangamo Biosciences (SGMO) Jumps: Stock Rises 7.2%
read full: http://finance.yahoo.com/news/sangamo-biosciences-sgmo-jumps-stock-123123365.html
*********************************************************
Mon, 08 Dec 2014 12:35:16 GMT ~ Sangamo BioSciences Presents New Data at American Society of Hematology Meeting Demonstrating Broad Application of ZFN Mediated Genome-Editing Approach to Therapeutics for Hemophilia and Lysosomal Storage Disorders
[at noodls] - December 8, 2014 Data Demonstrate Therapeutic Levels of Clotting Factor for Hemophilia in Non-Human Primates and In Vivo Protein Production of Lysosomal Storage Disease Enzymes RICHMOND, Calif., Dec. 8, ...
read full: http://www.noodls.com/view/33A671417680C5C572D3A7532CD47B589F985E81
*********************************************************
Mon, 08 Dec 2014 12:00:00 GMT ~ Sangamo BioSciences Presents New Data at American Society of Hematology Meeting Demonstrating Broad Application of ZFN Mediated Genome-Editing Approach to Therapeutics for Hemophilia and Lysosomal Storage Disorders
[PR Newswire] - RICHMOND, Calif., Dec. 8, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO) announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders (LSD) and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform (IVPRP) for the potentially curative treatment of such diseases, and were presented at the 56th Annual Meeting of the American Society of Hematology (ASH) held in San Francisco from December 5 to 9, 2014. The data presented at ASH from Sangamo's proprietary IVPRP applications demonstrated the efficient production, secretion and tissue uptake of functional iduronate-2-sulfatase and alpha-L-iduronidase, enzymes that are deficient in the LSDs, Hunter and Hurler's disease, respectively. "These data provide proof of concept for this broadly applicable genome editing strategy. We demonstrate that our process can be applied to multiple gene targets and is scalable to large animals supporting the potential application of the albumin gene as a safe harbor site for expression of therapeutic proteins," said Philip Gregory, D. Phil., Sangamo's senior vice president of research and chief scientific officer.
read full: http://finance.yahoo.com/news/sangamo-biosciences-presents-data-american-120000279.html
*********************************************************
Wed, 19 Nov 2014 13:12:21 GMT ~ Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
[at noodls] - RICHMOND, Calif., Nov. 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that positive preclinical data from its joint program with Shire plc, to develop a novel ZFP Therapeutic® ...
read full: http://www.noodls.com/view/DD2E3FA030BA9F90ACB07ED56711CBCC7A2B10EC
*********************************************************
Wed, 19 Nov 2014 12:00:00 GMT ~ Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms
[PR Newswire] - RICHMOND, Calif., Nov. 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced that positive preclinical data from its joint program with Shire plc, to develop a novel ZFP Therapeutic ...
read full: http://finance.yahoo.com/news/sangamo-biosciences-presents-study-society-120000792.html
*********************************************************
$SGMO charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$SGMO company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/SGMO/company-info
Ticker: $SGMO
OTC Market Place: Not Available
CIK code: 0001001233
Company name: Sangamo BioSciences, Inc.
Incorporated In: DE, USA
$SGMO share structure
## source: otcmarkets.com
Market Value: $1,130,717,674 a/o Dec 12, 2014
Shares Outstanding: 68,403,973 a/o Oct 22, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$SGMO extra dd links
Company name: Sangamo BioSciences, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=SGMO+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=SGMO+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=SGMO+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/news - http://finance.yahoo.com/q/h?s=SGMO+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/SGMO/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=SGMO+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/SGMO
DTCC (dtcc.com): http://search2.dtcc.com/?q=Sangamo+BioSciences%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Sangamo+BioSciences%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Sangamo+BioSciences%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/SGMO
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001001233&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=SGMO&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=SGMO
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=SGMO+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=SGMO
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=SGMO
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=SGMO+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/SGMO/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=SGMO+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/SGMO.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=SGMO
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/SGMO/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/SGMO/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/SGMO
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/SGMO
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/SGMO:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=SGMO
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=SGMO
$SGMO DD Notes ~ http://www.ddnotesmaker.com/SGMO
Good SA article on Sangamo " Sangamo's Technology Can Possibly Advance New Treatments For Patients With HIV"
Talks about the future prospects of the HIV compound and the ability to manipulate genes.
A ton of insider trading sell off u would think this would be a buy out canidate not looking good
Engineered, zinc finger domain–containing recombinases for site-specific delivery of therapeutic genes
An engineered recombinase could enable nontoxic, site-specific delivery of therapeutic genes to the human genome. Further details on the research, next steps and licensing status are discussed in the article.
http://www.nature.com/scibx/journal/v7/n13/full/scibx.2014.383.html
This keeps breaking out, then consolidating, then breaking out again. The price touched 26 after hours, so that may be my price target, however, I may get out at 24. I watch the price action closely.
It's trading pretty normally right now..nothing too unexpected
Followers
|
86
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
797
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |